Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors.
Journal: European journal of medicinal chemistry
Published: February 18, 2026
Discovery of a "First-in-Class" Selective Multikinase (CDK4/6/9-AURKA/B) Inhibitor, LCI133, for Neuroblastoma.
Journal: Journal of medicinal chemistry
Published: November 06, 2025
SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2.
Journal: Antiviral research
Published: March 27, 2024
Recent advances in multitarget-directed ligands via in silico drug discovery.
Journal: Drug discovery today
Published: September 21, 2023
Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
Journal: Leukemia & lymphoma
Published: September 14, 2023
LC-MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies.
Journal: Biomedical chromatography : BMC
Published: February 02, 2023
Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection.
Journal: Structure (London, England : 1993)
Published: March 05, 2022
PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron.
Journal: Clinical and translational medicine
Published: December 28, 2021
Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor.
Journal: bioRxiv : the preprint server for biology
Published: March 10, 2021
Last Updated: 09/26/2026